Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Mauricette Michallet, MD PhD, Romain Buono, PharmD, Mohamad Sobh, PharmD, Solene Poirey, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, MD, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Aude Flechon, MD PhD, Helen Boyle, MD, Franck E Nicolini, MDPhD, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142355

Published: 2020

Journal Articles

Viral Reactivation in Acute Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: Stimulation of the Immune System

Sandrine Loron, MD, Mohamad Sobh, PharmD, Bruno Lina, MD PhD, Florence Ader, MD, Myriam Renault, CRA, Marie-Cecile Michallet, PhD, Hélène Labussière, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-142959

Published: 2020

Journal Articles

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Romain Buono, Solene Poirey, Isabela Pascu, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Lila Gilis, MD, Franck E Nicolini, MD PhD, Stephane Morisset, BioStat, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2019) 134 (Supplement_1): 5817.

https://doi.org/10.1182/blood-2019-130597

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Blood (2019) 134 (Supplement_1): 2618.

https://doi.org/10.1182/blood-2019-130642

Published: 2019

Journal Articles

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Mohamad Sobh, PharmD, Lothar B. Huebsch, MD, Mitchell Sabloff, MSc,MDFRCPC, Jill Fulcher, MDPhDMRCPI FRCPath(UK), Sultan Altouri, MDFRCPC, Michael Kennah, MD, Elizabeth Drouin, MD, David S. Allan, MD FRCPC, MSc, Harold Atkins, MD, Grace Christou, MD, Pierre Villeneuve, MD PhD, Alexandre P.Blanchard, PhD, Kelsey Maclellan, Ranjeeta Mallick, PhD MSc, BSc, Nicole B. Laferriere, MD PhD, Sathish Gopalakrishnan, MD, Sita D. Bhella, MD, Natasha Kekre, MDFRCPC, Christopher Bredeson, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3263.

https://doi.org/10.1182/blood-2019-122436

Published: 2019

Journal Articles

Real World Management of Patients with Acute Myeloid Leukemia: Results from French Cancer Population-Based Registries

Morgane Mounier, Mohamad Sobh, PharmD, Alain Monnereau, MD PhD, Xavier Troussard, MD, Marc Maynadie, MD PhD, Mauricette Michallet, MD PhD

Blood (2018) 132 (Supplement 1): 3540.

https://doi.org/10.1182/blood-2018-99-116509

Published: 2018

Journal Articles

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Franck-Emmanuel Nicolini, MD PhD, Stéphanie Désilets, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Vila, Stephane Morisset, Stat, Mohamad Sobh, PharmD, Mauricette Michallet, MD PhD, Valerie Dubois, MD

Blood (2018) 132 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2018-99-117733

Published: 2018

Journal Articles

Outcome of Patients Receiving Extracorporeal Photopheresis for Steroid Resistant Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Alexandre Deloire, CRA, Daniela Revesz, MD, Youcef Chelgoum, MD, Mohamed El-Hamri, CRA, Franck-Emmanuel Nicolini, MD PhD, Hélène Labussière, MD, Olivier Hequet, MD

Blood (2018) 132 (Supplement 1): 5720.

https://doi.org/10.1182/blood-2018-99-118206

Published: 2018

Journal Articles

Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Benefits and Risks for Disease Relapse

Sandrine Loron, MD, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Xavier Thomas, MD, Sophie Ducastelle, MD, Myriam Renault, CRA, Florence Ader, MD, Emilie Frobert, MD, Franck-Emmanuel Nicolini, MD PhD, Hélène Labussière, MD, Mauricette Michallet, MD PhD

Blood (2018) 132 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2018-99-118249

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Florence Ranchon, PharmD, Sandrine Leroy, MD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle, MD, Bruno Lina, MD PhD, Florence Morfin, MD, Myriam Renault, CRA, Florence Ader, MD, Catherine Rioufol, PharmD, Helene Labussiere, MD, Franck-Emmanuel Nicolini, MD PhD

Blood (2016) 128 (22): 3695.

https://doi.org/10.1182/blood.V128.22.3695.3695

Published: 2016

Journal Articles

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group

Blood (2016) 128 (22): 3696.

https://doi.org/10.1182/blood.V128.22.3696.3696

Published: 2016

Journal Articles

Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma

Mauricette Michallet, MD PhD, Colette Chapuis-Cellier, Dr, Christine Lombard, Dr, Mohamad Sobh, PharmD, Thomas Dejoie, PharmD, Helene Caillon, PharmD, Michel Attal, Philippe Moreau, Herve Avet-Loiseau, MD PhD

Blood (2016) 128 (22): 3245.

https://doi.org/10.1182/blood.V128.22.3245.3245

Published: 2016

Journal Articles

Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle, MD, Myriam Renault, CRA, Nathalie Tedone, CRA, Helene Labussiere, MD, Franck-Emmanuel Nicolini, MD PhD

Blood (2016) 128 (22): 5786.

https://doi.org/10.1182/blood.V128.22.5786.5786

Published: 2016

Journal Articles

Salvage Use of Ibrutinib after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Soceity for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancy and Lymphoma Working Parties

Mauricette Michallet, MD PhD, Peter Dreger, MD, Mohamad Sobh, PharmD, Jennifer Hoek, Data Manager, Ariane Boumendil, PhD, Lutz Muller, MD, Paolo Corradini, MD, Wolfgang Bethge, MD, Domenico Russo, MD, Nadira Durakovic, MD PhD, Michel van Gelder, MD PhD, Nicolaas PM Schaap, MD, Nicolaus Kroger, MD PhD, Johannes Schetelig, MD MSc

Blood (2016) 128 (22): 4659.

https://doi.org/10.1182/blood.V128.22.4659.4659

Published: 2016

Journal Articles

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Franck E Nicolini, MD PhD, Vincent Alcazer, MD, Stephanie Dulucq, PharmD, PhD, Marie Balsat, MD, Helene Labussiere, MD, Helene Lequeu, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2016) 128 (22): 1893.

https://doi.org/10.1182/blood.V128.22.1893.1893

Published: 2016

Journal Articles

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Franck E. Nicolini, MD PhD, Gaelle Fossard, MD, Valerie Coiteux, MD, Viviane Dubruille, MD, Vincent Alcazer, MD, Mohamad Sobh, PharmD, Pierre Mouchel, MD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD, Agnes Guerci, MD PhD

Blood (2016) 128 (22): 1894.

https://doi.org/10.1182/blood.V128.22.1894.1894

Published: 2016

Journal Articles

Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT

Blood (2016) 128 (22): 4657.

https://doi.org/10.1182/blood.V128.22.4657.4657

Published: 2016

Journal Articles

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Franck E. Nicolini, MD PhD, Marie Balsat, MD, Maud Lekieffre, MD, Vincent Alcazer, MD, Hélène Labussière-wallet, MD, Sarah Huet, PharmD, PhD, Sandrine Hayette, Stéphanie Dulucq, PharmD, PhD, Stéphane Morisset, Stat, Jeremy Ruby, CRA, Isabelle Tigaud, MD, Marie-Pierre Fort, CRA, Mael Heiblig, MD, Rémi Chapelon, CRA, Madeleine Etienne, CRA, Mohamad Sobh, PharmD, Francois-Xavier Mahon, MD PhD Professor, Mauricette Michallet, MD PhD, Gabriel Etienne, MD PhD

Blood (2015) 126 (23): 2774.

https://doi.org/10.1182/blood.V126.23.2774.2774

Published: 2015

Journal Articles

Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Xavier Thomas, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 4324.

https://doi.org/10.1182/blood.V126.23.4324.4324

Published: 2015

NARROW

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Viral Reactivation in Acute Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: Stimulation of the Immune System

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Real World Management of Patients with Acute Myeloid Leukemia: Results from French Cancer Population-Based Registries

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Outcome of Patients Receiving Extracorporeal Photopheresis for Steroid Resistant Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Benefits and Risks for Disease Relapse

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group

Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma

Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only